Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy

European Journal of Cancer

Volumn 51, Issue 17, 2015, Pages 2517-2524

  De Azambuja, Evandro ^a   Ameye, Lieveke ^a   Diaz, Marie ^b   Vandenbossche, Sandrine ^c   Aftimos, Philippe ^a   Hernández, Sara Bejarano ^a   Shih Li, Chao ^a   Delhaye, François ^a   Focan, Christian ^d   Cornez, Nathalie ^e   Vindevoghel, Anita ^f   Beauduin, Marc ^g   Lemort, Marc ^a   Paesmans, Marianne ^a   Suter, Thomas ^h   Piccart Gebhart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Centre Hospitalier Universitaire Ambroise Pare   (Belgium)

^c Centre Hospitalier interregional Edith Cavell   (Belgium)

^d Clinique Saint Joseph   (Belgium)

^e Centre Hospitalier Universitaire de Tivoli   (Belgium)

^f Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^g Hospital de Jolimont   (Belgium)

^h BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adjuvant therapy; Late cardiac toxicity; Node positive breast cancer

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TROPONIN T; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; DRUG MEGADOSE; EARLY CANCER; ECG ABNORMALITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEW YORK HEART ASSOCIATION CLASS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; ECHOCARDIOGRAPHY; ECHOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84948386269     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.08.011     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 2005 1687 1717
2. D. Levy, S. Kenchaiah, M.G. Larson, E.J. Benjamin, M.J. Kupka, K.K.L. Ho, and et al. Long-term trends in the incidence of and survival with heart failure N Engl J Med 347 18 2002 1397 1402
3. V.G. Kaklamani, and W.J. Gradishar Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 4 Suppl. 1 2003 S26 S33
4. M. Zambetti, A. Moliterni, C. Materazzo, M. Stefanelli, S. Cipriani, P. Valagussa, and et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation J Clin Oncol 19 1 2001 37 43
5. J.J. Doyle, A.I. Neugut, J.S. Jacobson, V.R. Grann, and D.L. Hershman Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study J Clin Oncol 23 34 2005 8597 8605
6. E.Z. Basar, F. Corapcioglu, K. Babaoglu, Y. Anik, G. Gorur Daglioz, and R. Dedeoglu Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors? Pediatr Hematol Oncol 31 3 2014 237 252
7. R. Jurcut, H. Wildiers, J. Ganame, J. D'Hooge, J. De Backer, H. Denys, and et al. Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 21 12 2008 1283 1289
8. G. Mercuro, C. Cadeddu, A. Piras, M. Dessì, C. Madeddu, M. Deidda, and et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers Oncologist 12 9 2007 1124 1133
9. I. Dorup, G. Levitt, I. Sullivan, and K. Sorensen Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function Heart Br Card Soc 90 10 2004 1214 1216
10. D. Cardinale, M. Civelli, and C.M. Cipolla Troponins in prediction of cardiotoxic effects Ann Oncol 17 1 2006 173 author reply 173-4
11. D. Cardinale, A. Colombo, M.T. Sandri, G. Lamantia, N. Colombo, M. Civelli, and et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 23 2006 2474 2481
12. P.J. Perik, E.G.E. De Vries, F. Boomsma, W.T.A. van der Graaf, D.T. Sleijfer, D.J. van Veldhuisen, and et al. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors Anticancer Res 25 5 2005 3651 3657
13. M.T. Meinardi, W.T.A. Van Der Graaf, J.A. Gietema, M.P. Van Den Berg, D.T. Sleijfer, E.G.E. De Vries, and et al. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques Heart Br Card Soc 88 1 2002 81 82
14. M.J. Piccart, A. Di Leo, M. Beauduin, A. Vindevoghel, J. Michel, C. Focan, and et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer J Clin Oncol 19 12 2001 3103 3110
15. E. De Azambuja, M. Paesmans, M. Beauduin, A. Vindevoghel, N. Cornez, C. Finet, and et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study J Clin Oncol 27 5 2009 720 725
16. J.S. Gottdiener, J. Bednarz, R. Devereux, J. Gardin, A. Klein, W.J. Manning, and et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials J Am Soc Echocardiogr 17 10 2004 1086 1119
17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 1 2002 111 117
18. G.A. Borg Psychophysical bases of perceived exertion Med Sci Sports Exerc 14 5 1982 377 381
19. S.E. Lipshultz, M.J. Adams, S.D. Colan, L.S. Constine, E.H. Herman, D.T. Hsu, and et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association Circulation 128 17 2013 1927 1995
20. S.H. Armenian, S.K. Gelehrter, T. Vase, R. Venkatramani, W. Landier, K.D. Wilson, and et al. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors Clin Cancer Res 20 24 2014 6314 6323
21. E.J. Chow, Y. Chen, L.C. Kremer, N.E. Breslow, M.M. Hudson, G.T. Armstrong, and et al. Individual prediction of heart failure among childhood cancer survivors J Clin Oncol 2014
22. M.C. Pinder, Z. Duan, J.S. Goodwin, G.N. Hortobagyi, and S.H. Giordano Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer J Clin Oncol 25 25 2007 3808 3815
23. P. Fumoleau, H. Roché, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, and et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results Ann Oncol 17 1 2006 85 92
24. R.S. Jiji, C.M. Kramer, and M. Salerno Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs J Nucl Cardiol 19 2 2012 377 388
25. R. Wassmuth, S. Lentzsch, U. Erdbruegger, J. Schulz-Menger, B. Doerken, R. Dietz, and et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study Am Heart J 141 6 2001 1007 1013
26. B.C. Drafts, K.M. Twomley, R. D'Agostino, J. Lawrence, N. Avis, L.R. Ellis, and et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease JACC Cardiovasc Imaging 6 8 2013 877 885
27. S. Kumar, R. Marfatia, S. Tannenbaum, C. Yang, and E. Avelar Doxorubicin-induced cardiomyopathy 17 years after chemotherapy Tex Heart Inst J Tex Heart Inst St Lukes Episcop Hosp Tex Child Hosp 39 3 2012 424 427
28. H. Okumura, K. Iuchi, T. Yoshida, S. Nakamura, M. Takeshima, H. Takamatsu, and et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity Acta Haematol 104 4 2000 158 163
29. I. Bautmans, M. Lambert, and T. Mets The six-minute walk test in community dwelling elderly: influence of health status BMC Geriatr 23 4 2004 6